Marco Tana

Dr. Marco Tana

SS Annunziata Hospital, Chieti, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
CTClaudio Tana
Claudio Tana
IDIginio Donatiello
Iginio Donatiello
Alessandro CaputoAlessandro Caputo
Alessandro Caputo
Marco TanaMarco Tana
Marco Tana
TNTeresa Naccarelli
Teresa Naccarelli
Maria Adele GiamberardinoMaria Adele Giamberardino
Maria Adele Giamberardino
Sarcoidosis is a chameleon disease of unknown etiology, characterized by the growth of non-necrotizing and non-caseating granulomas and manifesting with clinical pictures that vary on the basis of the organs that are mainly affected. Lungs and intrathoracic lymph nodes are the sites that are most often involved, but virtually no organ is spared from this disease. Histopathology is distinctive but not pathognomonic, since the findings can be found also in other granulomatous disorders. The knowledge of these findings is important because it could be helpful to differentiate sarcoidosis from the other granulomatous-related diseases. This review aims at illustrating the main clinical and histopathological findings that could help clinicians in their routine clinical practice.

1 February 2013 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
CTClaudio Tana
Claudio Tana
ETEmmanuele Tafuri
Emmanuele Tafuri
Marco TanaMarco Tana
Marco Tana
PMPaolo Martelletti
Paolo Martelletti
ANAndrea Negro
Andrea Negro
Maria Adele GiamberardinoMaria Adele Giamberardino
Maria Adele Giamberardino
The role of migraine as an independent risk factor for cardiovascular events has been debated for several years, while it is more established for ischemic stroke. Recently, new studies have examined the likelihood of migraine to determine cardiovascular events, supporting the hypothesis of a predominant role in patients with migraine with aura, the risk including both sexes. In the literature, multiple pathophysiological mechanisms are described to explain this association, and are here discussed. Furthermore, the emerging evidence that a higher headache frequency and long-term migraine may worsen the cardio-metabolic profile in migraineurs (e.g. with a higher Framingham risk score and risk of developing atherosclerosis, insulin resistance and metabolic syndrome) makes it increasingly necessary to reduce the number and severity of attacks, not only to alleviate the painful symptoms, but also to improve the prognosis in these patients.

29 March 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
GCGiulio Cocco
Giulio Cocco
APAndrea Delli Pizzi
Andrea Delli Pizzi
Marco SciosciaMarco Scioscia
Marco Scioscia
VRVincenzo Ricci
Vincenzo Ricci
Andrea BoccatondaAndrea Boccatonda
Andrea Boccatonda
Cosima SchiavoneCosima Schiavone
Cosima Schiavone
Endometriosis is a debilitating disease characterized by endometrial glands and stroma outside the endometrial cavity. Abdominal wall endometriosis (AWE) indicates the presence of ectopic endometrium between the peritoneum and the skin, including subcutaneous adipose tissue and muscle layers, often following obstetric and gynecological surgical procedures. AWE is a not infrequent gynecological surgical complication, due to the increasing number of cesarean sections worldwide. In this pictorial review, we discuss the importance of medical history and physical examination, including the main ultrasound features in the diagnosis of AWE.

26 July 2015 in Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
Marco TanaMarco Tana
Marco Tana
CTClaudio Tana
Claudio Tana
GCGiulio Cocco
Giulio Cocco
GIGiovanni Iannetti
Giovanni Iannetti
MRMarcello Romano
Marcello Romano
CSCosima Schiavone
Cosima Schiavone

27 May 2024 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
Marco TanaMarco Tana
Marco Tana
CTClaudio Tana
Claudio Tana
DRDavide Rossi
Davide Rossi
CMCesare Mantini
Cesare Mantini
SGSabina Gallina
Sabina Gallina
EPEttore Porreca
Ettore Porreca
Cardiac amyloidosis represents a spectrum of conditions characterized by the accumulation of insoluble fibrils, resulting in progressive deposition and myocardial dysfunction. The exact mechanisms contributing to the heightened risk of thromboembolic events and bleeding tendencies in cardiac amyloidosis remain unclear. Proteins such as transthyretin in transthyretin amyloidosis and light chains in light-chain amyloidosis, along with acute phase proteins in amyloid A (AA) amyloidosis, play complex roles in the coagulation cascade, affecting both coagulation initiation and fibrinolysis regulation. The increased occurrence of atrial fibrillation, systolic and diastolic left ventricular dysfunction, and atrial myopathy in patients with cardiac amyloidosis may predispose them to thrombus formation. This predisposition can occur regardless of sinus rhythm status or even with proper anticoagulant management. Bleeding events are often linked to amyloid deposits around blood vessels, which may increase capillary fragility and cause coagulation disturbances, leading to unstable international normalized ratio levels during anticoagulant therapy. Thus, comprehensive risk assessment for both thrombotic and hemorrhagic complications, especially before commencing anticoagulant therapy, is imperative. This review will explore the essential pathophysiological, epidemiologic, and clinical aspects of thromboembolic and bleeding risk in cardiac amyloidosis, evaluating the existing evidence and uncertainties regarding thrombotic and bleeding risk assessment and antithrombotic treatment.

15 October 2023 in Annals of Medicine
Verified
Journal Article
Open access
CTClaudio Tana
Claudio Tana
LMLivia Moffa
Livia Moffa
KFKatia Falasca
Katia Falasca
JVJacopo Vecchiet
Jacopo Vecchiet
Marco TanaMarco Tana
Marco Tana
MGMaria Adele Giamberardino
Maria Adele Giamberardino
Background: COVID-19 continues to present challenges in the care of older adults with frailty and/or comorbidities and very old patients, who can be hospitalized with severe COVID-19 despite full vaccination. Frailty is a heterogeneous syndrome characterized by an increased aging-related vulnerability due to a reduced physiological reserve and function of systemic organs, and is associated with an impairment of activities of daily living. Frail older adults remain at elevated risk of mortality from COVID-19 compared to older adults without frailty, and some pre-existing risk factors such as malnutrition, prolonged bed rest, and the association with comorbidities can aggravate the SARS-CoV-2 infection. Furthermore, the severity of COVID-19 can impact on long-term functioning of older patients surviving from the infection. Persistent symptoms are another emerging problem of the post-vaccination phase of pandemic, as most patients suffer from chronic symptoms which can become debilitating and affect the daily routine. Aim of this review: In this complex relationship, the evaluation of COVID-19 in vulnerable categories is still a matter of high interest and personalized care plans based on a comprehensive geriatric assessment, tailored interventions; specific therapeutic algorithms among older adults are thus recommended in order to improve the outcomes.